We're Hiring! Check Out Our Careers Page For Open Positions:
TrialStat eClinical Suite
TrialStat® delivers data solutions on-demand for pharmaceutical, biotechnology, medical device companies, Contract Research Organizations and Data Management companies. Our TrialStat eClinical Suite™ consists of three fully unified product offerings - EDC, Portal and CTMS. We stand alone in the industry with such an all-compassing suite of products for conducting clinical trials.
EDC + Portal + CTMS
Powerful Data Capture, Real-Time Reporting and Trial Management Functionality In a Single Unified Suite.
TrialStat EDC
TrialStat EDC is a scalable, hosted, Electronic Data Capture Suite for pilot / proof of concept studies, Phase I, II, III and IV studies. In addition, TrialStat EDC is an ideal choice for the unique requirements of Medical Device and Diagnostic studies. TrialStat EDC uses the latest technology, allowing all users complete system access via any web browser or mobile device.
Explore TrialStat EDC
Visit the TrialStat EDC page to explore additional information and download the TrialStat EDC Overview.
TrialStat Portal
TrialStat Portal provides ultimate study management through real-time visualization of all of your study data. It seamlessly integrates with all TrialStat products, offering flexible, customizable user dashboards to view and drill down into your data. Portal enables you to make critical decisions quickly and efficiently, to continuously maintain control of your study.
Explore TrialStat Portal
Visit the TrialStat Portal page to explore additional information and download the TrialStat Portal Overview.
TrialStat CTMS
TrialStat CTMS seamlessly captures and reports real-time dynamic data from clinical operations and data management functions. A variety of customizable reports are available through easy-to-use reporting dashboards. Real-Time reporting in a user-friendly empowers clinical teams to make decisions quicker and act sooner.
Explore TrialStat CTMS
Visit the TrialStat CTMS page to explore additional information and download the TrialStat CTMS Overview.
See TrialStat In Action
Request Your Personalized Demo. Our Clinical Team will organize a tailored demonstration of TrialStat EDC, TrialStat Portal and TrialStat CTMS based on your specific study requirements. You'll see first hand how the TrialStat unified features, blazing speed, configurable features and comprehensive functionality will help you run more efficient and cost effective studies.
Premium Modules & Custom Development Services
A Fully Unified eClinical Suite Offering EDC functionality with Randomization (IWRS), Inventory Management, Medical Coding and ePRO in a single platform.
Custom Development
TrialStat is unique in the industry, providing validated custom development services. As a matter of practice, we regularly include new features based on Sponsor requirements. Our expert Software Architects, Software Developers and Compliance Experts provide complete custom development services to meet your unique requirements while ensuring compliance with all relevant regulatory requirements such as 21 CFR Part 11, HIPAA and Privacy Shield.
Tired of Hearing "No" All The Time?
Do you have requirements for your studies which other EDC platforms can't support?
Don't worry, at TrialStat we've developed our technology specifically for you. Our Expert Clinical Consultants and Software Developers will work with you to implement the features you need within our Validated eClinical Suite.
Regulatory Compliance
TrialStat's entire Unified eClinical Suite is developed and deployed with an Agile Methodology and specifically engineered to comply with FDA 21 CFR Part 11 requirements for Electronic Records and Electronic Signatures. TrialStat maintains a Master Validation Plan and Change Control procedures.
A Unified eClinical Suite Delivering Real-Time Data
See TrialStat In Action
Request Your Personalized Demo. Our Clinical Team will organize a tailored demonstration of TrialStat EDC, TrialStat Portal and TrialStat CTMS based on your specific study requirements. You'll see first hand how the TrialStat unified features, blazing speed, configurable features and comprehensive functionality will help you run more efficient and cost effective studies.
Recent News, Updates & Announcements
Things are happening! Check back often or subscribe to our RSS Feed.
Meet with Christopher Kata at “DIA 2019” in Booth # 2633 on June 23rd – 27th in San Diego, CA
Meet with Christopher Kata, Director of Sales & Marketing on June 23rd – 27th 2019 at “DIA 2019” Booth # 2633 in San Deigo CA! Christopher Kata, Director of Sales & Marketing 905 999-1957 ckata@trialstat.com When: June 23rd – 27th 2019 Where: Booth # 2633 San Deigo Convention Center, 111 W Harbor Drive, San Deigo,…
Read More
WideTrial Partners With Oncotelic to Bring Expanded Access Platform to Cancer
WideTrial , one of TrialStat’s strategic partners has partnered with Oncotelic to bring the Expanded Access Platform to Cancer. June 03, 2019 (ACCESSWIRE via COMTEX) — SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2019 / WideTrial Inc., a third-party sponsor of Expanded Access programs, has begun a partnership with Oncotelic Inc., a wholly owned subsidiary…
Read More
FDA to Launch Expanded Access Pilot ‘Project Facilitate’
The goal of Project Facilitate is to make it easier for oncologists or healthcare providers without the regulatory experience or resources to navigate the single patient IND process. “Access to clinical trials and access to novel therapeutics for patients is still a problem. We know that not all oncologists or healthcare providers have the regulatory…
Read More
Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access –Looking Forward
In March of 2019 the FDA released this statement regarding the value of Expanded Access Programs and the FDA’s encouragement of Sponsors to consider providing them as options for Patient Populations. A few interesting statements worth highlighting in the statement: “Since 2010, drug sponsors and manufacturers have given the opportunity of such access to more…
Read More